Changes in Hong Kong stocks | Fu Hong Hanlin (02696) is now up nearly 9%. The company's three innovative solid tumor drugs, IND, were accepted at the same time

The Zhitong Finance App learned that Fu Hong Han Lin (02696) is now up nearly 9%. As of press release, it has risen 8.62% to HK$63.65, with a turnover of HK$29.028 million.

According to the news, on December 30, Fuhong Hanlin announced that the new drug clinical trial applications for the company's three potential innovators — DLL3xDLL3xCD28 four-specific TCE HLX3901 developed based on the self-developed T-cell adaptor (TCE) platform, the potentially best-in-class (BIC) novel KAT6A/B oral small molecule inhibitor HLX97, and the potential first-in-class (FIC) B7H3-sialic acid fusion protein HLX316 have all been accepted by the National Drug Administration. The above three products are all intended for the treatment of solid tumors.